drugset / Trial / NCT02746328
Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass
NaSingle-groupOpen-labelTreatment
Summary
This is a multiple site, proof of concept feasibility study to describe the effect of GTx-024 9 or 18 mg on physical function in female subjects, from protocol G200802, with ER+/AR+ breast cancer.
Timeline
- Start
- 2016-04
- Primary completion
- 2018-02
- Completion
- 2018-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enobosarm | Small molecule | 9 mg | — |
| Subject | Enobosarm | Small molecule | 18 mg | — |